Lysogene S.A. (LYSGF)
| Previous close | 3.5000 |
| Open | 3.5000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 3.5000 - 3.5000 |
| 52-week range | 2.4100 - 3.5000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 58.791M |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6670 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights
PARIS, January 13, 2022--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a gene therapy platform company targeting central nervous system (CNS) diseases, today announced the termination of its license agreement with Sarepta for LYS-SAF302, a phase 2/3 asset for the treatment of mucopolysaccharidosis Type IIIA (MPS IIIA), effective as of July 11, 2022. This termination follows unsuccessful discussions for transferring back to Lysogene the responsibility for the global commercial suppl
- Business Wire
Half-Year Report on the Liquidity Contract Signed by Lysogene with Kepler Cheuvreux
PARIS, January 05, 2022--Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today presents the half-year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux.
- Business Wire
Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB)
PARIS, December 24, 2021--Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has entered into a €15 million loan agreement with the European Investment Bank to accelerate the development of its gene therapy platform.
